Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Clinical trial NCT05775796 · COMPLETED

Trial details

NCT number: NCT05775796
Sponsor: Fudan University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Stage II-IIIA Immunotherapy Neoadjuvant Therapy

Start date: 2023-03-15
Primary completion: 2024-05-28
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.